We are live on
!
Find out more
ECM
Endurant Capital Management Portfolio holdings
AUM
$17.4M
1-Year Est. Return
7.38%
This Fund
S&P 500
This Quarter
Est. Return
+5.61%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$253M
AUM Growth
+$63.7M
(+34%)
Cap. Flow
+$59.7M
Cap. Flow
% of AUM
23.62%
Top 10 Holdings %
Top 10 Hldgs %
44.38%
Holding
92
New
44
Increased
11
Reduced
15
Closed
22
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
VCRA
VOCERA COMMUNICATIONS, INC.
VCRA
|
+$13.9M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$12.1M |
| 3 |
Gilead Sciences
GILD
|
+$10.4M |
| 4 |
Takeda Pharmaceutical
TAK
|
+$8.8M |
| 5 |
Icon
ICLR
|
+$8.14M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$14.6M |
| 2 |
CELG
Celgene Corp
CELG
|
+$10.8M |
| 3 |
CVS Health
CVS
|
+$8.43M |
| 4 |
SHPG
Shire pic
SHPG
|
+$8.02M |
| 5 |
DaVita
DVA
|
+$7.24M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 74.31% |
| 2 | Technology | 10.37% |
| 3 | Industrials | 2.87% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Iovance Biotherapeutics
IOVA
$1.93B
| – | – |
-318,185
| Closed | -$2.82M |
|
77
Johnson & Johnson
JNJ
$613B
| – | – |
-6,588
| Closed | -$850K |
|
78
Standard BioTools
LAB
$339M
| – | – |
-236,648
| Closed | -$2.04M |
|
79
McKesson
MCK
$96.8B
| – | – |
-4,966
| Closed | -$549K |
|
80
PetMed Express
PETS
$42.3M
| – | – |
-67,010
| Closed | -$1.56M |
|
81
Insulet
PODD
$11.8B
| – | – |
-40,727
| Closed | -$3.23M |
|
82
Sanofi
SNY
$102B
| – | – |
-81,401
| Closed | -$3.53M |
|
83
Stryker
SYK
$131B
| – | – |
-7,319
| Closed | -$1.15M |
|
84
Teva Pharmaceuticals
TEVA
$40.1B
| – | – |
-73,884
| Closed | -$1.14M |
|
85
UnitedHealth
UNH
$370B
| – | – |
-16,732
| Closed | -$4.17M |
|
86
Viatris
VTRS
$20.5B
| – | – |
-77,135
| Closed | -$2.11M |
|
|
NVRO
87
DELISTED
NEVRO CORP.
NVRO
| – | – |
-54,977
| Closed | -$2.14M |
|
|
MDRX
88
DELISTED
Veradigm Inc. Common Stock
MDRX
| – | – |
-591,533
| Closed | -$5.7M |
|
|
CELG
89
DELISTED
Celgene Corp
CELG
| – | – |
-168,609
| Closed | -$10.8M |
|
|
SHPG
90
DELISTED
Shire pic
SHPG
| – | – |
-46,100
| Closed | -$8.02M |
|
Similar funds
VAFP
CA
SCM
FWM
TOPU
CCMU
TGI
HSCU
Endurant Capital Management's Q1 2019 Portfolio in Review
As of Q1 2019, Endurant Capital Management held 92 positions worth $253M, up 34% from $189M the previous quarter. Its ten largest holdings account for 44% of the portfolio.
Endurant Capital Management deployed $59.7M of net new capital in Q1 2019, opening 44 new positions and adding to 11 existing holdings. Its largest new stake was VOCERA COMMUNICATIONS, INC.: 390,887 shares worth $12.4M.
By sector, the portfolio is most concentrated in Healthcare at 74% of assets, down from 91% a quarter earlier, followed by Technology and Industrials.
On the sell side, the largest reduction was Allergan plc, an estimated $14.6M trimmed.
- Endurant Capital Management's largest Q1 2019 buy was VOCERA COMMUNICATIONS, INC.: 390,887 shares worth $12.4M.
- Endurant Capital Management added most to Bristol-Myers Squibb in Q1 2019, an estimated $12.1M increase.
- Endurant Capital Management's biggest Q1 2019 reduction was Allergan plc, cutting an estimated $14.6M.
- Endurant Capital Management fully exited Celgene Corp in Q1 2019, selling an estimated $10.8M.
- Endurant Capital Management's ten largest holdings make up 44% of its $253M portfolio in Q1 2019.
- Endurant Capital Management opened 44 new positions and closed 22 in Q1 2019.
- Endurant Capital Management's portfolio value rose 34% quarter-over-quarter to $253M.
Based on Endurant Capital Management's 13F filing for Q1 2019, filed 15 May 2019.